You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2025

Details for New Drug Application (NDA): 202799

✉ Email this page to a colleague

« Back to Dashboard

NDA 202799 describes OMONTYS PRESERVATIVE FREE, which is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are two patents protecting this drug. Additional details are available on the OMONTYS PRESERVATIVE FREE profile page.

The generic ingredient in OMONTYS PRESERVATIVE FREE is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

Summary for 202799

Tradename:	OMONTYS PRESERVATIVE FREE
Applicant:	Takeda Pharms Usa
Ingredient:	peginesatide acetate
Patents:	2

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 202799

Generic Entry Date for 202799^: ⤷ Try for Free* Constraining patent/regulatory exclusivity: 7,550,433 Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	SOLUTION;INTRAVENOUS, SUBCUTANEOUS			Strength	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)
Approval Date:	Mar 27, 2012	TE:		RLD:	No
Patent:	7,550,433	Patent Expiration:	Jun 2, 2026	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
Patent:	7,919,461	Patent Expiration:	Jun 2, 2026	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE

Profile for product number 002

Active Rx/OTC/Discontinued:	DISCN	Dosage:	SOLUTION;INTRAVENOUS, SUBCUTANEOUS			Strength	EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)
Approval Date:	Mar 27, 2012	TE:		RLD:	No
Patent:	7,550,433	Patent Expiration:	Jun 2, 2026	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE

Expired US Patents for NDA 202799

Show entries

Subscribe to access the full database, or Try for Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Takeda Pharms Usa	OMONTYS	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-008	Mar 27, 2012	7,919,118	⤷ Try for Free
Takeda Pharms Usa	OMONTYS	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-007	Mar 27, 2012	7,084,245	⤷ Try for Free
Takeda Pharms Usa	OMONTYS	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-008	Mar 27, 2012	7,414,105	⤷ Try for Free
Takeda Pharms Usa	OMONTYS PRESERVATIVE FREE	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-004	Mar 27, 2012	7,414,105	⤷ Try for Free
Takeda Pharms Usa	OMONTYS PRESERVATIVE FREE	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-003	Mar 27, 2012	7,414,105	⤷ Try for Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Showing 1 to 5 of 5 entries

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.